The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study.

Abstract

e14032 Background: Anlotinib is a novel tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) 1/2/3, platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR) 1/2/3/4, c-Kit, and Ret. We report results from this retrospective study to determine the efficacy and tolerability of Anlotinib as a treatment for recurrent malignant glioma (rMG). Methods: A total of 26 eligible patients who relapsed from the standard chemoradiotherapy regimen (TMZ and radiotherapy) after surgery because of tumor located in the eloquent brain areas were enrolled in this study between May 2020 and August 2022. Patients were subjected to a concurrent treatment of Anlotinib (12mg qd) until disease progression or intolerable toxicity. Efficacy was evaluated using Response Assessment in Neuro-Oncology criteria for high-grade glioma. Safety was assessed using NCI-CTCAE 5.0. Survival was estimated with the Kaplan-Meier curve and log-rank test. Results: In total, 26 (11 male, 15 female) patients with recurrent malignant glioma were enrolled. The disease control rate was 84.6% (95%CI 36.9%-76.7%) and the objective response rate was 57.7%(95%CI 65.1%-95.6%). The median progress-free survival (PFS) for all patients was 9.0 months (95%CI 2.88-15.19). The most common treatment-related adverse events were hand-foot syndrome (38.5%), Weakness (38.5%), hypertension 30.8%) and there were no Grade ≥3 toxicities. Conclusions: The present study showed that anlotinib had a promising efficacy and favorable tolerability in treat rMG. Further randomized controlled clinical studies are needed to confirm the efficacy of Anlotinib for the treatment of rMG.